Generation of therapeutic microfoam
AssigneeBTG International Limited
InventorsAnthony David Harman, Paul Harper, Neil Pollock, Gary Stewart Sinclair
Life of this patent
Estimating the term…
Loading patent…
AssigneeBTG International Limited
InventorsAnthony David Harman, Paul Harper, Neil Pollock, Gary Stewart Sinclair
Estimating the term…
A method for producing a microfoam suitable for use in scleropathy of blood vessels comprises introducing a physiologically acceptable blood-dispersible gas into a container (1) holding an aqueous sclerosant liquid and releasing the mixture of blood-dispersible gas and sclerosant liquid, whereby upon release of the mixture the components of the mixture interact to form a microfoam.
A device for producing a microfoam suitable for use in scleropathy of blood vessels, comprising:
A device for producing a microfoam suitable for use in scleropathy of blood vessels, comprising:
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
Aerosols; Foams: foams; Dry foams
Drugs for disorders of the cardiovascular system: vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Separate rigid or semi-rigid containers joined to each other at their external surfaces: coaxially and provided with means facilitating admixture
Filling or charging means: delivery valves permitting filling or charging
Term ended 20 Feb 2025 (estimated)
The present invention relates to a method and apparatus for the generation of microfoam comprising a sclerosing material, particularly a sclerosing liquid, which is suitable for use in the treatment of various medical conditions involving blood vessels, particularly varicose veins and other disorders involving venous malformation.
Sclerosis of varicose veins is based on the injection into the veins of liquid sclerosant substances which, by inter alia causing a localised inflammatory reaction, favour the elimination of these abnormal veins. When a sclerosing substance is injected in liquid form, it is mixed with the blood contained in the vein and is diluted in an unknown proportion. The results are uncertain, owing to over-dosage or under-dosage, and are limited to short varicose segments. As the size of the varicose veins to be injected decreases, this dilution is less and the results obtained are more predictable.
Until recently, sclerosis was a technique selected in cases of small and medium varicose veins, those with diameters equal to or greater than 7 mm being treated by surgery. Sclerosis and surgery complemented one another but sclerosis treatment continued not to be applicable to large varicose veins. In these large varicose veins, if a sclerosing substance was injected, its concentration in the vein, its homogeneous distribution in the blood, and the time for which it is in contact with the internal walls of the vessel treated were not known.
FIG. 1 shows a cross-sectional view of a device of the second aspect of the invention incorporating a cam track mechanism, as further described in Example 1 below.
FIG. 2 shows an exploded view of a canister device of the second aspect incorporating a variant of the cam track mechanism of FIG. 1, as further described in Example 2 below, in which FIG. 2a shows the connector, FIG. 2b shows the complete assembly, FIG. 2c shows a cut-away portion of the connector, and FIG. 2d and FIG. 2e show cross-sections of the cam mechanism.
FIG. 3 shows an exploded view of a canister device of the second aspect incorporating a screw thread mechanism, as further described in Example 3 below, in which FIG. 3a shows the complete assembly FIG. 3b shows a cross-section of the assembled device.
FIG. 1 illustrates a device of the second aspect of the invention incorporating a cam track mechanism. The device comprises a container (1) for an aqueous sclerosant liquid, a container (2) for a physiologically acceptable blood-dispersible gas and an engaging means comprising a connector (3).
The device is designed to be used with the container (1) for the aqueous sclerosant liquid charged with 18 ml of a polidocanol formulation, comprising 1% polidocanol in a pH 7.3 phosphate-buffered aqueous solution including a small proportion of ethanol to solubilise the polidocanol, and a mixture of 75% CO2/25% N2 gas at 0.5 bar absolute pressure. The aerosol valve on the can continuously meters a specified mix ratio of liquid to gas to create a foam of specified density.
The container (2) for a physiologically acceptable blood-dispersible gas is charged with pure oxygen gas at 5.8 bar absolute pressure. It is used to pressurise the container (1) for the aqueous sclerosant liquid just before the microfoam is required, and is then discarded. The reason for adding the oxygen at the last moment before use is that polidocanol appears incompatible with long term exposure to pressurised oxygen.